Article and Video CATEGORIES
Denise has over 30 years of varying experience in the healthcare arena. In August 2009 she joined The Global Resource for Advancing Cancer Education as one of its first employees. She has grown with the organization and now oversees the operational movement of programs, efficiency, and effectiveness within the organization, as well as the daily processes and functions.
For our 18th video in the GRACE Spanish Lung Cancer Library, 
Dr. Brian Hunis, Medical Director, Head and Neck Cancer Program, Memorial Cancer Institute, Miami, Florida, joined GRACE to discuss the basics of Lung Cancer for Spanish-speaking patients and caregivers. In this video Dr. Hunis addresses acquired resistance to targeted therapies: biology and different clinical patterns.
TRANSCRIPTS - Spanish and English
Resistencia adquirida a las terapias dirigidas: Biología y diferentes patrones clínicos.
Lamentablemente inclusive en pacientes que tienen la translocación de ALK, eventualmente los pacientes van a desarrollar una resistencia adquirida, por lo cual la medicación con crizotinib no va a funcionar mas.
Por lo general, estos son pacientes que van a tener un prelapso o una recaída en sistema nervioso central o pulmón. Esos son pacientes a los cuales que uno va a considerar terapia de segunda línea o cambiar a quimioterapia.
Acquired resistance to targeted therapies: biology and different clinical patterns.
Unfortunately, even patients with ALK translocation will eventually develop an acquired resistance, resulting in crisotinib not working anymore.
In general, these patients will have a relapse or re-fall in the central nervous system or lung. In these patients, we will consider a second line therapy or change to chemotherapy.
Please feel free to offer comments and raise questions in our
discussion forums.
Related Content
